Emmaus Life Sciences, Inc., today announced receiving the coveted "No Action Indicated" classification following a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance program.
Read MoreEmmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year ended December 31, 2023.
Read MoreEmmaus reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.
Read MoreEmmaus Life Sciences, Inc. today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder).
Read MoreEmmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.
Read More